Dashboard
Manage Tickers

RGEN


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

repligen-lowers-fy2025-gaap-eps-guidance-from-085-092-to-082-085-vs-091-est-raises-fy2025-sales-guidance-from-715000m-735000m-to-729000m-737000m-vs-726458m-est
Repligen Lowers FY2025 GAAP EPS Guidance f...
10/28/2025 11:31:57

Repligen (NASDAQ:RGEN) lowers FY2025 GAAP EPS guidance from $0.85-$0.92 to $0.82-$0.85 vs $0.91 analyst estimate. Raises FY2025...

repligen-narrows-fy2025-adj-eps-guidance-from-165-172-to-165-168-vs-168-est-raises-fy2025-sales-guidance-from-715000m-735000m-to-729000m-737000m-vs-726458m-est
Repligen Narrows FY2025 Adj EPS Guidance f...
10/28/2025 11:31:47

Repligen (NASDAQ:RGEN) narrows FY2025 Adj EPS guidance from $1.65-$1.72 to $1.65-$1.68 vs $1.68 analyst estimate. Raises FY2025...

repligen-q3-adj-eps-046-beats-042-estimate-sales-188805m-beat-181338m-estimate
Repligen Q3 Adj. EPS $0.46 Beats $0.42 Est...
10/28/2025 11:30:33

Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.42 by 10....

earnings-scheduled-for-october-28-2025
Earnings Scheduled For October 28, 2025
10/28/2025 11:11:34

evercore-isi-group-maintains-outperform-on-repligen-raises-price-target-to-175
Evercore ISI Group Maintains Outperform on...
10/07/2025 17:51:20

Evercore ISI Group analyst Daniel Markowitz maintains Repligen (NASDAQ:RGEN) with a Outperform and raises the price target f...

barclays-maintains-overweight-on-repligen-raises-price-target-to-160
Barclays Maintains Overweight on Repligen,...
10/02/2025 13:30:44

Barclays analyst Luke Sergott maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $150 to $160.

what-8-analyst-ratings-have-to-say-about-repligen
What 8 Analyst Ratings Have To Say About R...
10/01/2025 20:01:23

hsbc-initiates-coverage-on-repligen-with-buy-rating-announces-price-target-of-150
HSBC Initiates Coverage On Repligen with B...
10/01/2025 17:22:44

HSBC analyst Yessica Sanchez initiates coverage on Repligen (NASDAQ:RGEN) with a Buy rating and announces Price Target of $150.

this-sarepta-therapeutics-analyst-turns-bullish-here-are-top-5-upgrades-for-monday
This Sarepta Therapeutics Analyst Turns Bu...
09/22/2025 12:43:32

evercore-isi-group-upgrades-repligen-to-outperform-raises-price-target-to-155
Evercore ISI Group Upgrades Repligen to Ou...
09/22/2025 11:33:53

Evercore ISI Group analyst Daniel Markowitz upgrades Repligen (NASDAQ:RGEN) from In-Line to Outperform and raises the price ...

jefferies-maintains-hold-on-repligen-lowers-price-target-to-135
Jefferies Maintains Hold on Repligen, Lowe...
09/12/2025 10:20:19

Jefferies analyst Matthew Stanton maintains Repligen (NASDAQ:RGEN) with a Hold and lowers the price target from $145 to $135.

analyst-expectations-for-repligens-future
Analyst Expectations For Repligen's Future
09/03/2025 12:00:50

hc-wainwright--co-reiterates-buy-on-repligen-maintains-180-price-target
HC Wainwright & Co. Reiterates Buy on Repl...
09/03/2025 10:49:16

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Repligen (NASDAQ:RGEN) with a Buy and maintains $180 price tar...

repligen-stock-outlook-risk-skewed-to-the-downside-through-2026
Repligen Stock Outlook: Risk Skewed To The...
07/31/2025 14:45:50

Repligen stock has been in a prolonged downtrend, and Adhishthana principles suggest more weakness ahead. Here's what inves...

repligen-partners-with-novasign-to-advance-digital-twins-and-predictive-process-control-for-bioprocessing-workflows
Repligen Partners With Novasign To Advance...
07/31/2025 11:38:04

rbc-capital-maintains-outperform-on-repligen-raises-price-target-to-204
RBC Capital Maintains Outperform on Replig...
07/30/2025 14:40:27

RBC Capital analyst Conor McNamara maintains Repligen (NASDAQ:RGEN) with a Outperform and raises the price target from $193 ...

wells-fargo-maintains-overweight-on-repligen-lowers-price-target-to-175
Wells Fargo Maintains Overweight on Replig...
07/30/2025 14:11:17

Wells Fargo analyst Brandon Couillard maintains Repligen (NASDAQ:RGEN) with a Overweight and lowers the price target from $1...

repligen-raises-fy2025-adj-eps-guidance-from-163-172-to-165-172-vs-168-est-raises-fy2025-sales-guidance-from-695000m-720000m-to-715000m-735000m-vs-709438m-est
Repligen Raises FY2025 Adj EPS Guidance fr...
07/29/2025 11:33:59

Repligen (NASDAQ:RGEN) raises FY2025 Adj EPS guidance from $1.63-$1.72 to $1.65-$1.72 vs $1.68 analyst estimate. Raises FY2025 ...

repligen-q2-adj-eps-037-misses-039-estimate-sales-182000m-beat-174831m-estimate
Repligen Q2 Adj. EPS $0.37 Misses $0.39 Es...
07/29/2025 11:33:02

Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.37 per share which missed the analyst consensus estimate of $0.39 by 5...

Core News & Articles
Earnings Scheduled For July 29, 2025
07/29/2025 08:32:31

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION